

Allergan plc  
Form 11-K  
June 21, 2018  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 11-K**

**ANNUAL REPORT**  
**Pursuant to Section 15(d) of the**  
**Securities Exchange Act of 1934**

**ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF**  
**1934**

**FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017**

**or**

**TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT**  
**OF 1934**

**Commission File Number 1-36867**

- A. Full title of the plan and address of the plan, if different from that of the issuer named below:

**ALLERGAN, INC.**

**RETIREMENT 401(k) PLAN**

**(formerly, ALLERGAN, INC.**

**SAVINGS AND INVESTMENT PLAN)**

**2525 Dupont Drive**

**Irvine, CA 92612**

- B. Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

**ALLERGAN PLC**

**Clonshaugh Business and Technology Park**

**Coolock, Dublin, D17 E400**

**Ireland**

**Table of Contents**

Allergan, Inc. Retirement 401(k) Plan (formerly, the Allergan, Inc. Savings and Investment Plan)

Index to Financial Statements

and Supplemental Schedules

	<b>Page</b>
<u>Report of Independent Registered Public Accounting Firm</u>	1
Financial Statements:	
<u>Statements of Net Assets Available for Benefits as of December 31, 2017 and 2016</u>	3
<u>Statement of Changes in Net Assets Available for Benefits for the Year Ended December 31, 2017</u>	4
<u>Notes to the Financial Statements</u>	5
Supplemental Schedules*:	
<u>Schedule H, Line 4i Schedule of Assets (Held at End of Year) at December 31, 2017</u>	14
<u>Schedule H, Line 4(a) Schedule of Delinquent Participant Contributions for the Year Ended December 31, 2017</u>	15
<u>Signatures</u>	16
<u>Index to Exhibits</u>	17
<u>Exhibit 23.1</u>	18

\* All other schedules required by the Department of Labor Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974 have been omitted because they are not applicable.

**Table of Contents**

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Plan Administrator, Participants and Beneficiaries of the Allergan, Inc. Retirement 401(k) Plan (formerly, Allergan, Inc. Savings and Investment Plan)

***Opinion on the Financial Statements***

We have audited the accompanying statements of net assets available for benefits of the Allergan, Inc. Retirement 401(k) Plan (formerly, Allergan, Inc. Savings and Investment Plan) (the Plan ) as of December 31, 2017 and 2016, and the related statement of changes in net assets available for benefits for the year ended December 31, 2017, and the related notes (collectively, the financial statements ). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2017 and 2016, and the changes in net assets available for benefits for the year ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America.

***Basis for Opinion***

These financial statements are the responsibility of the Plan s management. Our responsibility is to express an opinion on the Plan s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ( PCAOB ) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

***Report on Supplemental Information***

The supplemental information in the accompanying schedule of assets (held at end of year) as of December 31, 2017 and the supplemental schedule of delinquent participant contributions for the year ended December 31, 2017, have been subjected to audit procedures performed in conjunction with the audit of the Plan s financial statements. The supplemental information is the responsibility of the Plan s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the

**Table of Contents**

Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

/s/ EisnerAmper LLP

We have served as the Plan's auditor since March of 2015.

EISNERAMPER LLP

Iselin, New Jersey

June 20, 2018

**Table of Contents****Allergan, Inc. Retirement 401(k) Plan (formerly, the Allergan, Inc. Savings and Investment Plan)****Statements of Net Assets Available for Benefits****December 31, 2017 and 2016**

	<b>2017</b>	<b>2016</b>
<b>Assets</b>		
Investments, at fair value	\$ 2,321,000,110	\$ 2,006,241,928
Total investments	2,321,000,110	2,006,241,928
Notes receivable from participants	18,586,310	15,445,509
Other receivables	484,286	309,500
Contributions receivable		
Company	93,177,420	83,561,750
Participant	1,690	17,355
Total contributions receivable	93,179,110	83,579,105
Net assets available for benefits	\$ 2,433,249,816	\$ 2,105,576,042

See accompanying Notes to the Financial Statements.

**Table of Contents****Allergan, Inc. Retirement 401(k) Plan (formerly, the Allergan, Inc. Savings and Investment Plan)****Statement of Changes in Net Assets Available for Benefits****Year Ended December 31, 2017**

	<b>2017</b>
<b>Additions to net assets</b>	
Investment income	
Interest and dividend income	\$ 22,867,733
Net realized/unrealized appreciation in fair value of investments	241,419,789
<b>Total investment income</b>	<b>264,287,522</b>
Interest income from notes receivable from participants	767,751
<b>Contributions</b>	
Company	93,285,473
Participant	104,841,395
Rollovers	24,016,517
<b>Total contributions</b>	<b>222,143,385</b>
<b>Total additions to net assets</b>	<b>487,198,658</b>
<b>Deductions from net assets</b>	
Benefits paid to participants	265,150,191
Administrative expenses	671,785
<b>Total deductions from net assets</b>	<b>265,821,976</b>
<b>Net increase prior to transfer</b>	<b>221,376,682</b>
Transfer in of Acelity 401(k) Plan	73,599,480
Transfer in of Zeltiq Aesthetics 401k Plan	32,697,612
<b>Net increase</b>	<b>327,673,774</b>
<b>Net assets available for benefits</b>	
Beginning of year	2,105,576,042
<b>End of year</b>	<b>\$ 2,433,249,816</b>

See accompanying Notes to the Financial Statements.

---

**Table of Contents**

**Allergan, Inc. Retirement 401(k) Plan (formerly, the Allergan, Inc. Savings and Investment Plan)**

**Notes to the Financial Statements**

**Years Ended December 31, 2017 and 2016**

**1. Description of Plan**

The following description of the Allergan, Inc. Retirement 401(k) Plan (formerly known as the Allergan, Inc. Savings and Investment Plan) (the Plan) provides only general information. The Plan name was changed effective January 1, 2018 from Allergan, Inc. Savings and Investment Plan to Allergan, Inc. Retirement 401(k) Plan. Participants should refer to the Plan document for a more complete description of the Plan's provisions.

***General***

The Plan, established on July 26, 1989, is a defined contribution plan sponsored by Allergan, Inc. On March 17, 2015, Allergan plc (at the time known as Actavis plc) (the Company or the Employer) acquired Allergan, Inc. (the Allergan Acquisition). As a result of the Allergan Acquisition, the Company became the sponsor of the Plan. The Plan covers certain eligible employees of the Company as defined below. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (ERISA) and is qualified under the Internal Revenue Code (the Code). The administrator for the Plan is the Allergan Employee Benefits Committee (the Plan Committee). The Benefits Oversight Committee is charged with certain plan sponsor functions, which include the ability to amend and make certain design-related changes to the Plan, and the responsibility to monitor the performance of the Plan Committee and Investment Committee. The Fidelity Management Trust Company (Fidelity) is the Trustee and Fidelity Workplace Services LLC is the recordkeeper for the Plan.

During the year ended December 31, 2017, the Company completed the acquisition of LifeCell Corporation (LifeCell), a subsidiary of Acelyt L.P. Inc. The Statement of Changes in Net Assets Available for Benefits includes \$73,599,480 of assets which were held by the Acelyt 401(k) Plan and were transferred into the Plan. LifeCell eligible employees became eligible to participate in the Plan on March 27, 2017.

Also, during the year ended December 31, 2017, the Company completed the acquisition of Zeltiq Aesthetics, Inc. (Zeltiq). Effective October 1, 2017, the Zeltiq Aesthetics 401k Plan, including all assets held by the Zeltiq Aesthetics 401k Plan, was legally merged with and into the Plan. The Statement of Changes in Net Assets Available for Benefits includes \$32,697,612 that was transferred into the Plan. Zeltiq employees became eligible to participate in the Plan on October 1, 2017.

Effective October 3, 2016, the Allergan Inc. 401(k) Plan, the Kythera Biopharmaceuticals Inc. 401k Plan, the Durata Therapeutics 401(k) Plan, and the Oculeve 401(k) Plan and Trust, including all assets were legally merged with and into the Plan. Employees became eligible to participate in the Plan on October 3, 2016.

***Contributions and Eligibility***

The Plan provides for immediate participation of eligible employees in the Plan. The Company's eligible United States employees may contribute a portion of their compensation (as defined in the Plan), on a before tax basis, after tax basis (including Roth 401(k)), or a combination thereof, subject to the limitations set forth in the Plan and the Code.





**Table of Contents**

**Allergan, Inc. Retirement 401(k) Plan (formerly, the Allergan, Inc. Savings and Investment Plan)**

**Notes to the Financial Statements**

**Years Ended December 31, 2017 and 2016**

The Company's eligible United States employees are automatically enrolled in the Plan at a pre-tax contribution rate of 4% of compensation, as defined, unless the employee affirmatively elects a different rate. Effective October 1, 2017, the Plan also added an automatic escalation feature where by the deferral will increase each July 1st by 1% up to a maximum of 8%. Prior to October 3, 2016, the Company's eligible United States employees were enrolled with their respective affiliated plans. The Company's eligible United States employees were automatically enrolled in the Plan at a pre-tax contribution rate of 5% of compensation, as defined, unless the employee affirmatively elected a different rate.

Participants who have attained age 50 before the end of the Plan year are eligible to make catch-up contributions.

The Company's eligible Puerto Rico-based employees may contribute a portion of their compensation (as defined by the Plan), either on a before tax basis, after tax basis, or a combination thereof, subject to the limitations defined in the Plan and the Puerto Rico Internal Revenue Code.

Participants direct the investment of their contributions into various investment options offered by the Plan. Additionally, participants may elect to change their investment options and transfer their account balances among the different investment funds at any time, subject to the Company's Global Security Trading Policy. The Investment Committee, or its delegate, regularly consults with an investment advisor to evaluate investment performance and, based thereon, will add or remove investment options.

The Company match is 100% of the first 8% of a participant's contributions up to the IRS limit made on an annual basis to eligible employees as of the end of the Plan year. In addition to the matching contributions, the Company could also elect to make discretionary profit sharing contributions and the Company could also make additional matching contributions up to 4% of the participant deferred compensation based on the Company's achievement of certain performance goals. Employees are required to be employed by the Company on the last day of the Plan year to receive any employer contribution and discretionary profit sharing contribution, if any. Effective January 1, 2018, employees who have reached age 55 and have 5 years of credited service or who have reached their normal retirement age under the Plan will be eligible to receive the employer match, additional match and profit sharing even if they do not meet the last day requirement.

The Company made an additional matching contribution of 1% for the year ended December 31, 2017 based on the achievement of certain performance goals. For the year ended December 31, 2017, the Company did not make any discretionary profit sharing contributions. The Company did not make any additional matching or discretionary profit sharing contributions for the years ended December 31, 2016.

***Vesting***

Participant contributions are fully vested at all times. Effective January 1, 2016, participants who were active participants became fully vested for the Company matching, additional matching, and discretionary profit sharing contributions.

Edgar Filing: Allergan plc - Form 11-K

Prior to January 1, 2016, participants forfeited their share of non-vested employer contributions if they terminated their employment before becoming 100% vested. Employer matching contributions vested based on a cliff vesting of three years of service. After three years of service, all employer matching contributions were fully vested.

**Table of Contents**

**Allergan, Inc. Retirement 401(k) Plan (formerly, the Allergan, Inc. Savings and Investment Plan)**

**Notes to the Financial Statements**

**Years Ended December 31, 2017 and 2016**

***Participant Accounts***

Each participant's account is credited with the participant's contributions, employer contributions and allocations of fund earnings and charged with an allocation of administrative expenses and fund losses. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account. Participants direct the investment of their accounts.

***Notes Receivable from Participants***

Notes receivable from participants are measured at their unpaid principal balance, plus any accrued but unpaid interest. Participants may borrow a minimum of \$1,000 and a maximum equal to the lesser of \$50,000 or 50% of the participant's vested account balance. Each loan is collateralized by the participant's vested account balance and bears interest commensurate with local prevailing rates as determined by the Plan Committee. Repayment of principal and interest is provided by uniform payroll deductions over a period of up to five years for all loans unless loan proceeds were used to purchase a primary residence. The period for repayment of loans used for purchase of a primary residence have a maximum repayment term of 15 years. Principal and interest is paid ratably through payroll deductions. Effective October 1, 2017, terminated employees have the option to continue to repay their loans based on the repayment schedule. As of December 31, 2017, the rates of interest on outstanding loans ranged from 4.25% to 10.25% with various maturities through January 2033. Delinquent notes receivable from participants are reclassified as distributions based upon the terms of the Plan document.

***Payment of Benefits***

Upon termination of service due to separation from the Company (including due to death, disability, or retirement), a participant (or beneficiary, in case of the participant's death) may receive the value of his or her vested interest in a lump-sum distribution or rollover his or her vested interest to an IRA or another employer qualified plan, or the participant may leave his or her vested interest in the Plan if his or her account balance is greater than \$1,000 up until age 70½, at which time the participant will be required to take a lump-sum distribution or rollover the vested interest to an IRA or another qualified plan. Withdrawals are also permitted for financial hardship, which is determined pursuant to the provisions of the Code, and for a participant's vested account balance after age 59½.

***Forfeitures***

Forfeitures may be used by the Company to offset future employer contribution requirements, to reinstate rehired employee accounts and to pay plan expenses. As of December 31, 2017 and 2016, forfeited nonvested accounts totaled approximately \$1,123,000 and \$1,022,000, respectively.

***Administrative Expenses***

Edgar Filing: Allergan plc - Form 11-K

In the year ended December 31, 2017, the Plan paid recordkeeping and advisory expenses of approximately \$670,000. The expenses primarily related to advisory service fees, participant loan fees and distribution fees. Certain participant initiated administration fees are charged directly to the account balance of the participant requesting the service.

**Table of Contents**

**Allergan, Inc. Retirement 401(k) Plan (formerly, the Allergan, Inc. Savings and Investment Plan)**

**Notes to the Financial Statements**

**Years Ended December 31, 2017 and 2016**

***Plan Termination***

In the event the Board of Directors of Allergan, Inc. decides it is impossible or inadvisable for business reasons to continue the Plan, then it may, by resolution or by action of the Allergan Benefits Oversight Committee, terminate the Plan. In the event of Plan termination, the net assets of the Plan will be allocated among the participants or their beneficiaries, after payment of any expenses properly chargeable to the Plan, in accordance with the provisions of ERISA.

**2. Summary of Significant Accounting Policies**

***Basis of Accounting***

The financial statements are prepared on the accrual basis of accounting.

***Use of Estimates***

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America may require the Plan management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, and when applicable, disclosure of contingent assets and liabilities at the date of the financial statements. Accordingly, actual results could differ from those estimates.

***Risks and Uncertainties***

The Plan provides for various investment options. Investment securities are exposed to various risks including interest rate risk, market risk and credit risk. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is at least reasonably possible that changes in risks in the near term would materially affect participants' account balances and the amounts reported in the Statements of Net Assets Available for Benefits and the Statement of Changes in Net Assets Available for Benefits.

Volatility in the financial market may significantly impact the subsequent valuation of the Plan's investments. Accordingly, the valuation of investments at December 31, 2017 may not necessarily be indicative of amounts that could be realized in a current market exchange.

***Investment Valuation and Income Recognition***

The Plan's investments are stated at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. See Note 5 Fair Value Measurements for a discussion of fair value measurements. If available, quoted market prices are used to value investments.

Edgar Filing: Allergan plc - Form 11-K

Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Net appreciation/depreciation in value of investments are included the Plan's gains and losses on investments bought and sold as well as investments held during the year.

**Table of Contents**

**Allergan, Inc. Retirement 401(k) Plan (formerly, the Allergan, Inc. Savings and Investment Plan)**

**Notes to the Financial Statements**

**Years Ended December 31, 2017 and 2016**

***Payment of Benefits***

Payments to participants are recorded when paid.

**3. Related Party and Party in Interest Transactions**

Certain investments are managed by Fidelity Management Trust Company, who acts as the Plan trustee. These transactions qualify as party-in-interest transactions which are exempt from the prohibited transaction rules under ERISA.

The Plan paid approximately \$670,000 to Fidelity in fees and expenses for the year ended December 31, 2017.

The value of the Allergan plc ordinary shares is \$224,435,610 and \$337,110,627 as of December 31, 2017 and 2016, respectively. At December 31, 2017 and 2016, there were 1,372,023 and 1,605,212 ordinary shares of the Allergan plc stock held in the Plan, respectively.

Fidelity provides certain administrative services to the Plan and receives revenue from mutual fund providers for services the trustee provides to the funds. This revenue is used to offset certain amounts owed to Fidelity for its administrative services to the Plan. If the revenue received by Fidelity from such mutual fund service providers exceeds the amounts owed, Fidelity remits the excess to the Plan pursuant to the service agreement. Such amounts may be applied to pay the Plan administrative expenses or allocated to the accounts of the participants. During the year ended December 31, 2017, the Plan earned approximately \$482,000, which was received subsequent to December 31, 2017 and is reflected as a receivable on the statement of net assets available for benefits and included in net realized/unrealized appreciation in fair value of investments on the statement of changes in net assets available for benefits. This amount will be used to pay administrative expenses in the 2018 plan year.

The Plan also allows for the issuance of notes receivable to participants in accordance with the related regulations. These transactions also qualify as party-in-interest transactions for which there is a statutory exemption.

**4. Tax Status**

The Plan obtained its latest determination letter on March 25, 2014, in which the Internal Revenue Service stated that the Plan, as then designed, was in compliance with the applicable requirements of the Code. The Plan has been amended and restated since receiving the determination letter. However, the Plan's administrator and the Plan's tax counsel believe that the Plan is currently designed and being operated in compliance with the applicable requirements of the Code and constitutes a qualified plan under Section 401(a) of the Code and that the Plan's trust is exempt from federal income taxes under provisions of Section 501(a).



Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by a government authority. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that

---

**Table of Contents**

**Allergan, Inc. Retirement 401(k) Plan (formerly, the Allergan, Inc. Savings and Investment Plan)**

**Notes to the Financial Statements**

**Years Ended December 31, 2017 and 2016**

as of December 31, 2017 and 2016, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

**5. Fair Value Measurements**

Accounting Standard Codification ( ASC ) 820 provides the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under Financial Accounting Standards Board ASC 820 are described as follows:

***Basis of Fair Value Measurement***

- Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.
- Level 2 Inputs to the valuation methodology include: (1) quoted prices for similar assets or liabilities in active markets; (2) quoted prices for identical or similar assets or liabilities in inactive markets; (3) inputs other than quoted prices that are observable for the asset or liability; or (4) inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.
- Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The following is a description of the valuation methodologies used for assets measured at fair value at December 31, 2017 and 2016. There have been no changes in the methodologies used at December 31, 2017 and 2016.

*Allergan plc ordinary shares* Valued at the closing price reported on the active market on which the individual securities are traded. The Plan held \$224,435,610 and \$337,110,627 of Allergan plc ordinary shares as of December 31, 2017 and 2016, respectively.

*Mutual funds* Valued at the net asset value ( NAV ) of shares held by the Plan at year end using the daily closing price. Mutual funds held by the Plan are deemed to be actively traded. Excessive trading in these investments will result in the limitation or prohibition of additional purchases (other than contribution and loan repayments) for 85 calendar days; additional excess trading will result in a limitation of one exchange day per calendar quarter for a 12 month period.

**Table of Contents**

**Allergan, Inc. Retirement 401(k) Plan (formerly, the Allergan, Inc. Savings and Investment Plan)**

**Notes to the Financial Statements**

**Years Ended December 31, 2017 and 2016**

*Collective trust funds* Valued at the NAV of units of a collective trust. The NAV, as provided by the trustee, is used as a practical expedient to estimate fair value. The NAV is based on the fair value of the underlying investments held by the fund less its liabilities. This practical expedient is not used when it is determined to be probable that the fund will sell the investment for an amount different than the reported NAV. Participant transactions (purchases and sales) may occur daily. Excessive trading in these investments will result in the limitation or prohibition of additional purchases (other than contribution and loan repayments) for 85 calendar days; additional excess trading will result in a limitation of one exchange day per calendar quarter for a 12 month period. Certain funds have a 90 day restriction on exchanging into a competing fund.

The following additional information presents the fund strategy relative to Plan investments reported on net asset value at December 31, 2017:

- (a) Galliard Managed Income Fund sought safety of principal and consistency of returns while attempting to maintain minimal volatility. The fund was primarily comprised of investment contracts including Guaranteed Investment Contracts. Before exchanging from Galliard Managed Income Fund into a competing fund, an individual must first exchange to a non-competing fund for 90 days.
- (b) T. Rowe Price Stable Value Common Trust Fund N seeks to maximize current income and maintain principal stability by investing primarily in a diversified portfolio of guaranteed investment contracts, bank investment contracts, synthetic investment contracts, and/or separate account contracts. Before exchanging from T. Rowe Price Stable Value Common Trust Fund N into a competing fund, an individual must first exchange to a non-competing fund for 90 days. The fund is closed to new investments, including contributions or exchanges.
- (c) Vanguard Target Date Funds seeks to provide capital appreciation and current income consistent with its current asset allocation. The funds invest in Vanguard mutual funds using an asset allocation strategy designed for investors planning to retire and leave the workforce in or within a few years of a specified target year. The fund's asset allocation will become more conservative over time. Within seven years after the target date, the fund's asset allocation should resemble that of the Target Retirement Income Trust Plus.
- (d) BlackRock Russell 2500<sup>®</sup> Index Fund is invested in portfolio of equity securities with the objective of approximating as closely as practicable the capitalization weighted total return of the segment of the United States market for publicly traded equity securities represented by the Russell 2500<sup>®</sup> Index. BlackRock uses a passive or indexing approach to try to achieve the fund's investment objective.

- (e) BlackRock Equity Index Fund is invested in a portfolio of equity securities with the objective of approximating as closely as practicable the capitalization weighted total rate of return of that segment of the United States market for publicly traded equity securities represented by the larger capitalized companies. The criterion for selection of investments shall be the S&P 500<sup>®</sup> Index. BlackRock uses a passive or indexing approach to try to achieve the fund's investment objective.
  
- (f) BlackRock U.S. Debt Index Fund is invested in a portfolio of debt securities with the objective of approximating as closely as practicable the total rate of return of the market for debt securities as defined by the Bloomberg Barclays U.S. Aggregate Bond Index. BlackRock uses a passive or indexing approach to try to achieve the fund's investment objective.

**Table of Contents****Allergan, Inc. Retirement 401(k) Plan (formerly, the Allergan, Inc. Savings and Investment Plan)****Notes to the Financial Statements****Years Ended December 31, 2017 and 2016**

- (g) BlackRock MSCI ACWI ex-U.S. IMI Index Fund is invested in a portfolio of international equity securities whose total rates of return will approximate as closely as practicable the capitalization weighted total rates of return of the markets in certain countries for equity securities traded outside the United States. The primary criterion for selection of investments in the Fund shall be the MSCI ACWI ex-U.S. IMI Index<sup>SM</sup>. BlackRock uses a passive or indexing approach to try to achieve the fund's investment objective.

The valuation methods used by the Plan may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The following table discloses by level the fair value hierarchy of the Plan's assets at fair value as of December 31, 2017 and 2016:

	<b>Fair Value Measurements as of December 31,</b>			
	<b>2017:</b>			
	<b>Total</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Company stock	\$ 224,435,610	\$ 224,435,610	\$	\$
Mutual funds	481,987,575	481,987,575		
Common collective trusts (A)	1,614,576,925			
<b>Total investments at fair value</b>	<b>\$ 2,321,000,110</b>	<b>\$ 706,423,185</b>	<b>\$</b>	<b>\$</b>

	<b>Fair Value Measurements as of December 31,</b>			
	<b>2016:</b>			
	<b>Total</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Company stock	\$ 337,110,627	\$ 337,110,627	\$	\$
Mutual funds	315,802,470	315,802,470		
Common collective trusts (A)	1,353,328,831			
<b>Total investments at fair value</b>	<b>\$ 2,006,241,928</b>	<b>\$ 652,913,097</b>	<b>\$</b>	<b>\$</b>

(A) Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this table are

intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Statements of Net Assets Available for Benefits.

**6. Mutual Fund Fees**

Investments in mutual funds are subject to sales charges in the form of front-end loads, back-end loads or 12b-1 fees. 12b-1 fees are ongoing fees allowable under Section 12b-1 of the Investment Company Act of 1940. These annual fees are used to pay for marketing and distribution costs of the funds. These fees are deducted prior to the allocation of the Plan's investment earnings activity, and thus not separately identifiable as an expense.

**Table of Contents****Allergan, Inc. Retirement 401(k) Plan (formerly, the Allergan, Inc. Savings and Investment Plan)****Notes to the Financial Statements****Years Ended December 31, 2017 and 2016****7. Reconciliation of Financial Statements to the Form 5500**

The following is a reconciliation of net assets available for benefits per the financial statements to the Form 5500:

	<b>December 31,</b>	
	<b>2017</b>	<b>2016</b>
Net assets available for benefits per the financial statements	\$ 2,433,249,816	\$ 2,105,576,042
Deemed loans from active employees	(12,110)	(14,333)
<b>Net assets available for benefits per Form 5500</b>	<b>\$ 2,433,237,706</b>	<b>\$ 2,105,561,709</b>

The following is a reconciliation of net increase to net assets prior to transfer per the financial statements to the Form 5500:

	<b>Year Ended</b>	
	<b>December 31, 2017</b>	
Net increase to net assets prior to transfer per financial statements	\$	221,376,682
Add prior year deemed loans from active employees		14,333
Less deemed loans from active employees		(12,110)
<b>Net increase to net assets prior to transfer per Form 5500</b>	<b>\$</b>	<b>221,378,905</b>

**8. ERISA Litigation**

On February 14, 2017, an ERISA complaint was filed in the federal district court in California against the Plan Committees of the Company's retirement plan alleging that the Committees breached their duties in investing in the Company's stock when they knew or should have known of the purported conduct that allegedly occurred between February 2014 and November 2016, specifically that Allergan and certain of its officers made materially false and misleading statements regarding the Company's internal controls over its financial reporting and failed to disclose that its Actavis generics unit had engaged in illegal, anticompetitive price-fixing with its generic industry peers. A similar ERISA complaint was filed on March 7, 2017 in the federal district court in New Jersey with substantially identical allegations. In July 2017, plaintiffs made a motion to consolidate the cases in the federal district court in New Jersey and filed a consolidated complaint in October 2017. The consolidated ERISA complaint asserts claims on behalf of a



putative class of individuals who participated in the Company's retirement plans and seeks an unspecified amount of damages and other injunctive relief. The Company filed a motion to dismiss the consolidated complaint in February 2018. The Company believes it has meritorious defenses and intends to defend itself vigorously. Therefore, given the early stages of this litigation the likelihood of any particular outcome or its potential impact cannot be determined at this time.

**Table of Contents****Allergan, Inc. Retirement 401(k) Plan (formerly, the Allergan, Inc. Savings and Investment Plan)**

EIN: 95-1622442 PN: 002

**Schedule H, Line 4i Schedule of Assets (Held at End of Year)**

December 31, 2017

Identity of issuer, borrower, lessor or similar party	Description of investment including maturity date, rate of interest, collateral, par or maturity value	Current Value
<b>Common stock:</b>		
* Allergan Stock	Ordinary Shares	\$ 224,435,610
<b>Mutual funds:</b>		
Dodge & Cox	Common Stock Fund	103,927,516
American Funds	New Perspective-R6 Fund	40,308,959
Loomis	Large Cap Growth Fund	91,503,202
Metropolitan West	Total Return Bond Fund	68,446,699
American Funds	EuroPacific Growth-R6 Fund	65,816,690
Eaton Vance Atlanta Capital	Mid-Cap Growth Fund	111,984,509
		481,987,575
<b>Collective Trust Funds</b>		
Vanguard	Index Retirement NL-O Fund	19,163,185
Vanguard	Index 2015 NL-O Fund	40,464,239
Vanguard	Index 2020 NL-O Fund	123,019,681
Vanguard	Index 2025 NL-O Fund	194,388,245
Vanguard	Index 2030 NL-O Fund	212,765,141
Vanguard	Index 2035 NL-O Fund	231,598,172
Vanguard	Index 2040 NL-O Fund	236,337,585
Vanguard	Index 2045 NL-O Fund	148,449,924
Vanguard	Index 2050 NL-O Fund	60,482,681
Vanguard	Index 2055 NL-O Fund	22,573,243
Vanguard	Index 2060 NL-O Fund	5,493,129
Black Rock	Equity Index Fund	133,650,147
Black Rock	U.S. Debt Index Fund	30,198,448
Black Rock	Russell 2500® Index Fund	51,748,895
Black Rock	MSCI ACWI ex-U.S. IMI Index Fund	44,690,391
T. Rowe Price	Stable Value Fund	927,521
Galliard	Stable Value Fund	58,626,298
		1,614,576,925

\*Participant Loans with various maturities through January 2033 with interest rates ranging from 4.25% to 10.25%

18,574,200

\$2,339,574,310

\* Party-in-interest for which a statutory exemption exists.

**Table of Contents****Allergan, Inc. Retirement 401(k) Plan (formerly, the Allergan, Inc. Savings and Investment Plan)**

EIN: 95-1622442 PN: 002

**Schedule H, Line 4(a) Schedule of Delinquent Participant Contributions**

For the year ended December 31, 2017

Participant Contributions transferred late to the plan	Amount withheld	Date withheld	Date Remitted	Check here if participant loan repayments are included	Contributions not corrected	Contributions corrected outside the VFCP	Contributions pending correction in VFCP	Total fully corrected under VFCP and PTE 2002-51
	\$ 3,114	12/31/2014	1/23/2015		\$ 3,114**	\$	\$	\$
	545	1/8/2016	1/26/2016		545*			
	9,256	6/30/2016	7/25/2016		9,256**			
	56,740	9/30/2016	11/18/2016		56,740**			
	17,416	12/30/2016	1/27/2017		17,416**			
	\$ 87,071				\$ 87,071	\$	\$	\$

\* All employee contributions have been remitted to the Plan. The Plan sponsor is in the process of finalizing lost earnings.

\*\* The Plan Sponsor remitted \$543 of lost earnings to the Plan.

**Table of Contents**

**Allergan, Inc. Retirement 401(k) Plan (formerly, the Allergan, Inc. Savings and Investment Plan)**

**Signatures**

**The Plan**

Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

**Allergan, Inc. Retirement 401(k) Plan**

By: Allergan plc as Plan Administrator

By: **/s/ KAREN LING**

Karen Ling

Chairperson, Employee Benefit Plans  
Committee

Dated: June 20, 2018

**Table of Contents**

**Allergan, Inc. Retirement 401(k) Plan**

**Index to Exhibits**

Exhibit Number	Description
23.1	Consent of Independent Registered Public Accounting Firm